Development of vaccines against Plasmodium falciparum malaria: taking lessons from naturally acquired protective immunity.
The acquisition of substantial anti-malarial protection in people naturally exposed to P. falciparum is often cited as evidence that malaria vaccines can be developed, but is rarely used to guide the development. We are pursuing the development of vaccines based on antigens and immune responses that appear key in naturally acquired protection.
Hviid
Lars
L
Department of Infectious Diseases, Centre for Medical Parasitology, Copenhagen University Hospital (Rigshospitalet) and University of Copenhagen, Copenhagen, Denmark. lhcmp@rh.dk
D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D002809:Chondroitin Sulfates / Q000378:metabolism; D004912:Erythrocytes / Q000469:parasitology; D005260:Female; D006801:Humans; D007110:Immunity, Active / Q000276:immunology; D017780:Malaria Vaccines / Q000276:immunology*; D016778:Malaria, Falciparum / Q000276:immunology* / Q000378:metabolism; D010920:Placenta / Q000469:parasitology; D010963:Plasmodium falciparum / Q000276:immunology* / Q000378:metabolism; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000276:immunology; D015800:Protozoan Proteins / Q000276:immunology
D000953:Antigens, Protozoan; D017780:Malaria Vaccines; D015800:Protozoan Proteins; C085731:erythrocyte membrane protein 1, Plasmodium falciparum; D002809:Chondroitin Sulfates